2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMOPending
The primary objective of Do CHANGE is to develop a health ecosystem for integrated disease management of citizens with high bloodpressure and patients with ischemic heart disease or heart failure. The system will give them access to a set of…